Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to approve it…